+ Watch SGNT
on My Watchlist
Trading below IPO price, and did get as high as $29 last July. How much it's actually worth is hard to say with stocks this newly public, but insider trade is giving buy signals now so odds are good they share analyst confidence of this going from red ink to black this year.
Low-risk diversification strategy across multiple drugs.
Looks like its consolidating from the S&P downgrade. The price just moved above its 50 day lin reg line so I bet in a few weeks it will regress back to it.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions